| Icatibant Basic information |
| Product Name: | Icatibant |
| Synonyms: | RRP-(HYP)-G-(THI)-S-(D-TIC)-(OIC)-R;H-D-ARG-ARG-PRO-HYP-GLY-THI-SER-D-TIC-OIC-ARG-OH;H2N-D-ARG-ARG-PRO-HYP-GLY-THI-SER-D-TIC-OIC-ARG-OH;Icatibatide Acetate;Icatibant;D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin;D-Arg-L-Arg-L-Pro-L-t4Hyp-Gly-L-Thi-L-Ser-D-Tic-L-Oic-L-Arg-OH;H0E-140 |
| CAS: | 130308-48-4 |
| MF: | C59H89N19O13S |
| MW: | 1304.52 |
| EINECS: | 0 |
| Shelf life | 2 years |
| Source | Synthetic |
 |
|
| Icatibant Chemical Properties |
| density | 1.60±0.1 g/cm3(Predicted) |
| storage temp. | Sealed in dry,2-8°C |
| solubility | Water:100.0(Max Conc. mg/mL);76.66(Max Conc. mM) |
| form | powder |
| pka | 3.60±0.21(Predicted) |
| color | white |
| Water Solubility | Soluble to 1 mg/ml in water |
| CAS DataBase Reference | 130308-48-4 |
| Icatibant Usage And Synthesis |
| Uses | Antagonist (bradykinin). |
| Definition | ChEBI: A ten-membered synthetic oligopeptide consisting of D-Arg, Arg, Pro, Hyp, Gly, Thi, Ser, D-Tic, Oic, and Arg residues joined in sequrence. A bradykinin receptor antagonist used as its acetate salt for the treatment of acut attacks of hereditary angioedema in adult patients. |
| Description | Icatibant is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011. |
